Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

Table 4 Sensitivity analysis of NK₁RA co-administration for non-CR, non-CC, and non-TC during the overall study period

	PS-matched analysis			PS-adjusted analysis			IPTW
	OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value
A: non-CR
NK₁RA inclusive regimen (yes vs no)	2.10	0.36–12.11	0.406	1.50	0.36–6.31	0.579	2.25	0.59–8.58	0.233
B: non-CC
NK₁RA inclusive regimen (yes vs no)	2.69	0.49–14.69	0.253	1.95	0.48–7.89	0.348	2.74	0.70–10.67	0.146
C: non-TC
NK₁RA inclusive regimen (yes vs no)	1.41	0.44–4.46	0.561	1.77	0.61–5.11	0.293	2.68	1.07–6.72	0.036

OR odds ratio; CI confidence interval; CR complete response; CC complete control; TC total control; PS propensity score; IPTW inverse probability of treatment weighting.

ISSN: 1471-2407